Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAPDH | P04406 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352466 | 1.00 | RNASE1 (0.50) | RNASE1POLBUPP1NPC1MEN1 | |
| SCHEMBL12352467 | 0.90 | RNASE1 (0.58) | RNASE1POLBUPP1NPC1MEN1 | |
| SCHEMBL2623806 | 0.90 | RNASE1 (0.58) | RNASE1POLBUPP1NPC1MEN1 | |
| SCHEMBL30976632 | 0.83 | POLB (0.52) | RNASE1POLBUPP1NPC1MEN1 | |
| SCHEMBL7653783 | 0.82 | RNASE1 (0.65) | RNASE1POLBUPP1MEN1USP2 | |
| SCHEMBL13273272 | 0.82 | RNASE1 (0.65) | RNASE1POLBUPP1MEN1USP2 | |
| SCHEMBL2623807 | 0.82 | RNASE1 (0.65) | RNASE1POLBUPP1MEN1USP2 | |
| SCHEMBL2632480 | 0.82 | RNASE1 (0.65) | RNASE1POLBUPP1MEN1USP2 | |
| SCHEMBL6842685 | 0.82 | RNASE1 (0.65) | RNASE1POLBUPP1MEN1USP2 | |
| SCHEMBL14263441 | 0.79 | RNASE1 (0.56) | RNASE1POLBUPP1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-7795238-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7589079-B2 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine | NOVARTIS AG (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080015350-A1 | Crystalline and amorphous forms of beta-L-2'-deoxythymidine | NOVARTIS AG (CH) | 2008-01-17 | — | — | US | disclosed |
| US-7186700-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | RNASE1 473/4885POLB 65/4885UPP1 72/4885 |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | SLC28A2, SLC29A2, PNP | RNASE1 1059/4885POLB 66/4885UPP1 198/4885 |
| US-20080015350-A1 | Crystalline and amorphous forms of beta-L-2'-deoxythymidine | TYMP, PYGL, TTR | RNASE1 41/4885POLB 235/4885UPP1 38/4885 |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | RNASE1 473/4885POLB 65/4885UPP1 72/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | RNASE1 473/4885POLB 65/4885UPP1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.